New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:34 EDTTRGTTargacept reports Q4 EPS (40c), consensus (39c)
Reports Q4 net revenue $93,000 vs. $590,000 a year ago. Based on current operating plans, Targacept expects its operating expenses for the year ending December 31, 2014 to be in the range of $40M-$45M, and its cash, cash equivalents and investments balance at December 31, 2014 to be at least $100M. Targacept does not expect significant operating revenues for the year ending December 31, 2014, based on current operating plans. In addition, Targacept continues to expect that its current cash resources will be sufficient to meet its operating requirements at least through the end of 2015. This financial guidance includes both cash and non-cash revenue and expense items.
News For TRGT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
08:41 EDTTRGTTargacept says Catalyst CEO Nassim Usman to become CEO of combined company
Catalystís CEO Nassim Usman, Ph.D., will become the President and CEO of the combined company and the other Catalyst executive officers, Ed Madison, Ph.D., CSO and Fletcher Payne, CFO will assume their respective positions in the combined company. The seven-member board of directors of the combined company will be comprised of current Catalyst directors Harold E. Selick, Ph.D., Jeff Himawan, Ph.D., and Augustine Lawlor, as well as Dr. Usman, and current Targacept directors John P. Richard, Errol B. DeSouza, Ph.D. and Dr. Stephen A. Hill. Dr. Selick will serve as the new chairman of the board.
08:39 EDTTRGTTargacept, Catalyst Biosciences amend definitive merger agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use